Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Duke Institute for Brain Sciences | UNKNOWN |
| Alzheimer's Association | OTHER |
| Duke-NUS Graduate Medical School | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this study is to create new retinal imaging processing software useful for the development of novel retinal biomarkers of cognitive impairment associated with Alzheimer's disease (AD).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| mild cognitive impairment |
| ||
| mild to moderate cognitive impairment |
| ||
| normal or control group |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| spectral-domain optical coherence tomography (SD-OCT) | Other | Intervention same to all groups. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Nerve fiber layer/ganglion cell layer (NFL/GCL) abnormality score | The study will determine the significance of difference in NFL/GCL score between the AD subject groups at baseline. | Baseline |
| NFL/GCL abnormality score | The study will determine the significance of difference in NFL/GCL score between the AD subject groups at baseline. Dependent on baseline results, some subjects may have the opportunity to have another measurement taken at 12 months. | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Drusen/plaque score | The study will determine the significance of difference in peripheral drusen/amyloid plaque score between the AD subject groups at baseline. | Baseline |
| Drusen/plaque score |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Normal controls and patients with mild, mild to moderate cognitive impairment
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Heather Whitson, MD, MHS | Duke University | Principal Investigator |
| Eleonora Lad, MD, PhD | Duke University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Duke University Medical Center | Durham | North Carolina | 27710 | United States |
Not provided
| ID | Term |
|---|---|
| D060825 | Cognitive Dysfunction |
| ID | Term |
|---|---|
| D003072 | Cognition Disorders |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
The study will determine the significance of difference in peripheral drusen/amyloid plaque score between the AD subjects groups at baseline. Dependent on baseline results, some subjects may have the opportunity to have a second measurement at 12 months.
| 12 months |
| Total drusen area | The study will determine the significance of difference in total drusen area between the AD subject groups at baseline. | Baseline |
| Total drusen area | The study will determine the significance of difference in total drusen area between the AD subject groups at baseline. Dependent on baseline results, some subjects may have the opportunity to have a second measurement taken at 12 months. | 12 months |